IART · Integra Lifesciences Holdings Corp
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 29, 2026TL;DR. Integra reported Q2 revenue of $418.8M (+0.8% reported, +0.7% organic) and adjusted EPS of $0.56 above the high end of guidance, driven by tariff favorability and operational execution. The company reaffirmed its full-year organic revenue growth guidance of 0.8%-3.3% and adjusted EPS guidance of $2.40-$2.50, while updating reported revenue outlook for FX and noting an expected Q4 SurgiMend relaunch.
- + Adjusted EPS of $0.56 beat the high end of guidance, up 24% YoY from $0.45
- + Adjusted EBITDA margin expanded ~160 bps to 18.7% from 17.1%, with adjusted gross margin up ~60 bps to 61.3%
- + Operating cash flow rose to $22.8M from $8.9M, with leverage down to 4.1x from 4.5x at year-end
- + Braintree manufacturing restarted, building inventory for Q4 SurgiMend relaunch with PMA label expansion expected in 2027
- + Specialty Surgery organic revenue grew 1.6%, led by Neurosurgery +1.9% on Certas Plus, CUSA, and Bactiseal
- − Tissue Reconstruction revenue declined 2.0% organically, with Wound Reconstruction down mid-single digits on Integra Skin and MicroMatrix weakness
- − ENT revenue declined low single digits amid ongoing sinus balloon reimbursement pressure
- − Higher interest expense from planned refinancing expected in 2H 2026
- − Reported revenue guidance range lowered to $1.654-$1.695B from $1.662-$1.702B due to stronger USD/FX
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IART
this stock
Integra Lifesciences Holdings Corp
|
$1.25B | +2.1% | +1.5% | — | 8.8% |
|
ABT
Abbott Laboratories
|
$174.90B | -22.2% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.1% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -55.3% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IART | -21.3% | -22.9% | +23.8% | -22.1% | +2.1% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -21.1% | -22.4% | +11.7% | -23.0% | -10.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.